Oral squamous cell carcinoma (OSCC), AIF-1 gene (Allograft inflammatory factor), North Indian population, Genotyping, TaqMann assay


Objective: Oral Squamous Cell Carcinoma (OSCC), which is the sixth most prevalent type of cancer across the globe caused by cigarette smoking, smokeless tobacco use, excessive and extreme alcohol use, oral trauma, HPV (Human Papilloma Virus) infection as well as genetic mutations. AIF-1(Allograft Inflammatory Factor) has been identified as an inflammatory response modulator, and its increased expression has been linked to carcinogenesis.

Methods: In this study, 200 OSCC patients and 200 matched controls were compared to investigate if there was any association between the AIF-1(Allograft Inflammatory Factor) gene and the risk of cancer of oral cavity in the North Indian population. AIF-1(Allograft Inflammatory Factor) gene polymorphism rs2857595 were detected using TaqMan probe assay.

Results: The findings of our study revealed that AA genotype of AIF-1(Allograft Inflammatory Factor) Gene increases the susceptibility of Oral Squamous Cell Carcinoma. The association of AA genotype with Oral Squamous Cell Carcinoma is more in co-dominant model and the combination of both the mutant genotypes (AA+AG) is more significantly associated with Oral Squamous Cell Carcinoma in recessive model. GG genotype of AIF-1 (Allograft Inflammatory Factor) gene comes out with a protective effect against the risk of (OSCC Squamous Cell Carcinoma). To further understand the role of AIF-1(Allograft Inflammatory Factor) polymorphism, we compared the association of genotypes with various clinicopathological characteristics of Oral Squamous Cell Carcinoma patients. And we found that the patients with AA genotype have a significantly higher risk of developing high-grade tumors and more nodal involvement.

Conclusion: Thus, rs2857595 locus AA genotype of AIF-1(Allograft Inflammatory Factor) can be considered as important point in the development of accurate preventive approach and a prognostic indicator for oral cancer.


Download data is not yet available.


Gupta B, Bray F, Kumar N, Johnson NW. Associations between oral hygiene habits, diet, tobacco and alcohol and risk of oral cancer: a case–control study from India. Cancer Epidemiol. 2017;51:7-14. doi: 10.1016/j.canep.2017.09.003, PMID 28968558.

Laprise C, Shahul HP, Madathil SA, Thekkepurakkal AS, Castonguay G, Varghese I. Periodontal diseases and risk of oral cancer in Southern India: results from the HeNCe Life study. Int J Cancer. 2016;139(7):1512-9. doi: 10.1002/ijc.30201, PMID 27215979.

Sharma S, Satyanarayana L, Asthana S, Shivalingesh KK, Goutham BS, Ramachandra S. Oral cancer statistics in India on the basis of first report of 29 population-based cancer registries. J Oral Maxillofac Pathol. 2018;22(1):18-26. doi: 10.4103/jomfp.JOMFP_113_17, PMID 29731552.

Das S, Mukherjee S, Choudhury S, Bose A, Roy S. Antioxidant and cytotoxic activities of areca catechu seed extract in swiss albino mice using eac cell line in different culture medium. Int J Curr Pharm Sci. 2020;12(2):20-7. doi: 10.22159/ijcpr.2020v12i2.37481.

Sumintarti MR, Hajrah Yusuf ASt. Oral hairy leukoplakia manifestations related to CD4 count in HIV/AIDS patients at Dr Wahidin Sudirohusodo hospital. Int J Appl Pharm. 2019;11(4):57-9. doi: 10.22159/ijap.2019.v11s4.35292.

Chhaparwal Y, M Pai K, Kamath Ms, Carnelio S, Chhaparwal S. Efficacy and safety of tetrahydro curcuminoid in the treatment of oral leukoplakia: a pilot study. Asian J Pharm Clin Res 2018;11(12). doi: 10.22159/ajpcr.2018.v11i12.28107.

Veluthattil AC, Sudha SP, Kandasamy S, Chakkalakkoombil SV. Effect of hypofractionated, palliative radiotherapy on quality of life in late-stage oral cavity cancer: a prospective clinical trial. Indian J Palliat Care. 2019;25(3):383-90. doi: 10.4103/IJPC.IJPC_115_18, PMID 31413453.

Jiang X, Shapiro DJ. The immune system and inflammation in breast cancer. Mol Cell Endocrinol. 2014;382(1):673-82. doi: 10.1016/j.mce.2013.06.003, PMID 23791814.

Freeman MR, Li Q, Chung LW. Can stroma reaction predict cancer lethality? Clin Cancer Res. 2013;19(18):4905-7. doi: 10.1158/1078-0432.CCR-13-1694, PMID 24009149.

Mohammed ZM, Going JJ, Edwards J, Elsberger B, McMillan DC. The relationship between lymphocyte subsets and clinicopathological determinants of survival in patients with primary operable invasive ductal breast cancer. Br J Cancer. 2013;109(6):1676-84. doi: 10.1038/bjc.2013.493, PMID 23982600.

Klintrup K, Makinen JM, Kauppila S, Vare PO, Melkko J, Tuominen H. Inflammation and prognosis in colorectal cancer. Eur J Cancer. 2005;41(17):2645-54. doi: 10.1016/j.ejca.2005.07.017, PMID 16239109.

Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet. 2000;355(9200):248-50. doi: 10.1016/S0140-6736(00)00019-2, PMID 10675068.

Utans U, Arceci RJ, Yamashita Y, Russell ME. Cloning and characterization of allograft inflammatory factor-1: a novel macrophage factor identified in rat cardiac allografts with chronic rejection. J Clin Invest. 1995;95(6):2954-62. doi: 10.1172/JCI118003, PMID 7769138.

Deininger MH, Meyermann R, Schluesener HJ. The allograft inflammatory factor-1 family of proteins. FEBS Lett. 2002;514(2-3):115-21. doi: 10.1016/s0014-5793(02)02430-4, PMID 11943136.

Jia J, Bai Y, Fu K, Sun ZJ, Chen XM, Zhao YF. Expression of allograft inflammatory factor-1 and CD68 in haemangioma: implication in the progression of haemangioma. Br J Dermatol. 2008;159(4):811-9. doi: 10.1111/j.1365-2133.2008.08744.x, PMID 18647307.

Watano K, Iwabuchi K, Fujii S, Ishimori N, Mitsuhashi S, Ato M. Allograft inflammatory factor-1 augments production of interleukin-6, -10 and -12 by a mouse macrophage line. Immunology. 2001;104(3):307-16. doi: 10.1046/j.1365-2567.2001.01301.x, PMID 11722645.

Zhao YY, Yan DJ, Chen ZW. Role of AIF-1 in the regulation of inflammatory activation and diverse disease processes. Cell Immunol. 2013;284(1-2):75-83. doi: 10.1016/j.cellimm.2013.07.008, PMID 23948156.

Khirade MF, Lal G, Bapat SA. Derivation of a fifteen-gene prognostic panel for six cancers. Sci Rep. 2015;5(1):13248. doi: 10.1038/srep13248, PMID 26272668.

Jia J, Cai Y, Wang R, Fu K, Zhao YF. Overexpression of allograft inflammatory factor-1 promotes the proliferation and migration of human endothelial cells (HUV-EC-C) probably by up-regulation of basic fibroblast growth factor. Pediatr Res. 2010;67(1):29-34. doi: 10.1203/PDR.0b013e3181bf572b, PMID 19745784.

Elizondo DM, Andargie TE, Haddock NL, da Silva RLL, de Moura TR, Lipscomb MW. IL-10-producing CD8+CD122+PD-1+regulatory T cells are expanded by dendritic cells silenced for allograft inflammatory factor-1. J Leukoc Biol. 2019;105(1):123-30. doi: 10.1002/JLB.1A0118-010RR, PMID 30512224.

Khirade MF, Lal G, Bapat SA. Derivation of a fifteen-gene prognostic panel for six cancers. Sci Rep. 2015;5:13248. doi: 10.1038/srep13248, PMID 26272668.

Tandon D, Dewangan J, Srivastava S, Garg VK, Rath SK. miRNA genetic variants: as potential diagnostic biomarkers for oral cancer. Pathol Res Pract. 2018;214(2):281-9. doi: 10.1016/j.prp.2017.10.002, PMID 29103762.

Roman ID, Cano Martinez D, Lobo MV, Fernandez Moreno MD, Hernandez Breijo B, Sacristan S. Infliximab therapy reverses the increase of allograft inflammatory factor-1 in serum and colonic mucosa of rats with inflammatory bowel disease. Biomarkers. 2017;22(2):133-44. doi: 10.1080/1354750X.2016.1252950, PMID 27781498.

Zhang L, Deng S. Association of snps of aif-1 gene with susceptibility to oral cancer in Chinese population. Food Sci Technol. 2021;41(2)Suppl 2:769-74. doi: 10.1590/fst.38520.

Wei Q, Yu D, Liu M, Wang M, Zhao M, Liu M. Genome-wide association study identifies three susceptibility loci for laryngeal squamous cell carcinoma in the Chinese population. Nat Genet. 2014;46(10):1110-4. doi: 10.1038/ng.3090, PMID 25194280.

Sahu KB. Cyto-histopathological correlation of premalignant and oral cavity malignant lesions in a tertiary care hospital: cyto-histopathological correlation of premalignant and oral cavity malignant lesions. Asian J Pharm Clin Res. 2023;16(6):47-51.



How to Cite

TANDON, D. “AIF-1 GENE AS STRONG PROGNOSTIC BIOMARKER FOR ORAL CANCER”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 15, no. 9, Sept. 2023, pp. 37-41, doi:10.22159/ijpps.2023v15i9.48115.



Original Article(s)